Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 1 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Tonic Medical, Inc. has 2 pending office actions in the Biotechnology & Pharmaceuticals area. Both of these actions are assigned to 1 examiner, COHEN, MICHAEL P, and 1 distinct art unit. COHEN, MICHAEL P is the busiest examiner with 2 pending office actions. This concentration allows for a very consistent prosecution strategy, as the same examiner is reviewing all pending work in the same art unit. This is the most concentrated possible structure for a portfolio with multiple pending actions.
The 1 distinct art unit indicates a very specific technical focus for the company's biotechnology and pharmaceutical innovations. Because both actions are under the same examiner, the company can leverage insights from one case to inform the strategy for the other. Practitioners should focus their efforts on understanding the specific preferences and past decisions of COHEN, MICHAEL P. This concentrated profile simplifies the management of the portfolio, as there is only one examiner relationship and one set of art unit standards to navigate. The outcome of both 2 pending office actions will likely be influenced by the same examiner's perspective.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| COHEN, MICHAEL P | 2 | 58.7% | +27.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19350447 | DRUG-RELEASING COATING | COHEN, MICHAEL P | — |
| 19081631 | POLYMER-ENCAPSULATED DRUG PARTICLES | COHEN, MICHAEL P | — |
| Art Unit | Apps |
|---|---|
| 1612 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19350447 | DRUG-RELEASING COATING | COHEN, MICHAEL P | 1612 | §103Other | Non-Final OA | — | Pending | Oct 06, 2025 |
| 19081631 | POLYMER-ENCAPSULATED DRUG PARTICLES | COHEN, MICHAEL P | 1612 | §103 | Non-Final OA | — | Pending | Mar 17, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial